BlackRock Fund Advisors’s Evoke Pharma EVOK Stock Holding History

BlackRock Fund Advisors’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$63K	Buy	216 +31	+17%	+$8.03K	﹤0.01%	3707
2016 Q3	$60K	Buy	185 +101	+120%	+$46.2K	﹤0.01%	3727
2016 Q2	$83K	Buy	84 +78	+1,300%	+$61.2K	﹤0.01%	3717
2016 Q1	$5K	Buy	6 +1	+20%	+$512	﹤0.01%	4083
2015 Q4	$2K	Buy	+5	New	+$2.54K	﹤0.01%	4294

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 24.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock Fund Advisors's EVOK Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Evoke Pharma (EVOK) stake by 17% in Q4 2016, buying an estimated $8.03K and bringing the position to 216 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #3707.

BlackRock Fund Advisors first reported a position in EVOK in Q4 2015 and has held it in 5 quarters since. The position peaked at $83K in Q2 2016. 14 funds tracked by Wall St. Rank hold EVOK as of Q4 2016.

BlackRock Fund Advisors held 216 shares of Evoke Pharma worth $63K as of Q4 2016.
BlackRock Fund Advisors bought 31 Evoke Pharma shares in Q4 2016, an estimated $8.03K.
Evoke Pharma made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3707 holding.
BlackRock Fund Advisors first reported a position in Evoke Pharma in Q4 2015 and has held it in 5 quarters since.
BlackRock Fund Advisors's Evoke Pharma position peaked at $83K in Q2 2016.
14 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.